G protein coupled receptors (GPCRs) exhibit a spectrum of functional behaviours in response to natural and synthetic ligands. Recent crystal structures provide insights into inactive states of several GPCRs. Efforts to obtain an agonist-bound active-state GPCR structure have proven difficult due to the inherent instability of this state in the absence of a G protein. We generated a camelid antibody fragment (nanobody) to the human b 2 adrenergic receptor (b 2 AR) that exhibits G protein-like behaviour, and obtained an agonist-bound, active-state crystal structure of the receptor-nanobody complex. Comparison with the inactive b 2 AR structure reveals subtle changes in the binding pocket; however, these small changes are associated with an 11 Å outward movement of the cytoplasmic end of transmembrane segment 6, and rearrangements of transmembrane segments 5 and 7 that are remarkably similar to those observed in opsin, an active form of rhodopsin. This structure provides insights into the process of agonist binding and activation.
G protein coupled receptors (GPCRs) exhibit a spectrum of functional behaviours in response to natural and synthetic ligands. Recent crystal structures provide insights into inactive states of several GPCRs. Efforts to obtain an agonist-bound active-state GPCR structure have proven difficult due to the inherent instability of this state in the absence of a G protein. We generated a camelid antibody fragment (nanobody) to the human b 2 adrenergic receptor (b 2 AR) that exhibits G protein-like behaviour, and obtained an agonist-bound, active-state crystal structure of the receptor-nanobody complex. Comparison with the inactive b 2 AR structure reveals subtle changes in the binding pocket; however, these small changes are associated with an 11 Å outward movement of the cytoplasmic end of transmembrane segment 6, and rearrangements of transmembrane segments 5 and 7 that are remarkably similar to those observed in opsin, an active form of rhodopsin. This structure provides insights into the process of agonist binding and activation.
GPCRs activated by diffusible ligands have a spectrum of functional states 1 . A GPCR may activate more than one G protein isoform or a G-protein-independent pathway such as arrestin. In the absence of a ligand, many GPCRs exhibit some basal, agonist independent activity towards one or more of these signalling pathways. Orthosteric ligands (compounds that occupy the native hormone-binding pocket) are classified according to their efficacy, that is, the effect that they have on receptor signalling through a specific pathway. Inverse agonists inhibit basal activity whereas agonists maximally activate the receptor. Partial agonists induce submaximal activity, even at saturating concentrations. Neutral antagonists have no effect on basal activity, but sterically block the activity of other ligands. Moreover, the efficacy profile of ligands for a given GPCR can differ for different downstream signalling pathways. The presence of some activity in the unliganded receptor implies low energy barriers between functional states, such that thermal fluctuations significantly sample activating conformations, and ligands with distinct efficacy profiles act by stabilizing distinct subsets of conformations.
We know little about the structural basis for the functional versatility of GPCRs. Only rhodopsin has been crystallized in different conformational states [2] [3] [4] [5] . The first structures of rhodopsin covalently bound to 11-cis-retinal represent a completely inactive state with virtually no basal activity 5 . Structures of opsin, the ligand-free form of rhodopsin, obtained from crystals grown at pH 5.6 are likely to represent active conformations 2,3 , as the Fourier transform infrared (FTIR) spectrum of opsin at acidic pH resembles that of metarhodopsin II, the light-activated form of rhodopsin 6 . For rhodopsin, the light-induced transition from the inactive to the active state is very efficient. Rhodopsin is activated by photoisomerization of a covalent ligand, with efficient transfer of energy from the absorbed photon to the receptor. Crystal structures of low-pH opsin reveal that the protein conformation is the same in the presence or absence of a peptide from the alpha subunit of transducin (Gt), its cognate G protein, consistent with the notion that metarhodopsin II can adopt a fully active conformation in the absence of Gt.
The crystal structures of GPCRs activated by diffusible ligands, including the human b 2 AR 7-10 , the avian b 1 AR 11 , and the human adenosine A 2A receptor 12 , represent inactive conformations bound by inverse agonists. Unlike the activation of rhodopsin by light, agonists are much less efficient at stabilizing the active state of the b 2 AR, making it difficult to capture this state in a crystal structure. Fluorescence lifetime studies show that even saturating concentrations of the full agonist isoproterenol do not stabilize a single active conformation 13 . This may be due to the relatively low affinity and rapid rates of association and dissociation for b 2 AR agonists. However, in a companion manuscript we show that, even when bound to a covalent agonist, the b 2 AR crystallizes in an inactive conformation 14 . Experiments using a b 2 AR labelled with a conformationally sensitive fluorescent probe show that stabilization of the active state requires both agonist and Gs, the stimulatory G protein for adenylyl cyclase 15 . Efforts to obtain an agonist-GPCR-G protein complex are of great importance; however, this is a particularly difficult endeavour due to the biochemical challenges in working with both GPCRs and G proteins, and the inherent instability of the complex in detergent solutions. As an alternate approach, we developed a binding protein that preferentially binds to and stabilizes an active conformation, acting as a surrogate for Gs.
Nanobody-stabilized b 2 AR active state
The active G protein coupled state of the b 2 AR (and many other family A GPCRs) has characteristic functional properties. Agonists promote Gs binding to the b 2 AR and G protein binding to the receptor increases agonist affinity. We identified a camelid antibody fragment that exhibits G protein-like behaviour towards the b 2 AR. Tylopoda (camels, dromedaries and llamas) have developed a unique class of functional antibody molecules that are devoid of light chains 16 . A nanobody (Nb) is the recombinant minimal-sized intact antigen-binding domain of such a camelid heavy chain antibody and is approximately 25% the size of a conventional Fab fragment. To generate receptorspecific nanobodies, a llama was immunized with purified agonistbound b 2 AR reconstituted at high density into phospholipid vesicles. A library of single-chain nanobody clones was generated and screened against agonist bound receptor. We identified seven clones that recognized agonist-bound b 2 AR. Of these, Nb80 was chosen because it showed G-protein-like properties upon binding to both wild-type b 2 AR and b 2 AR-T4L, the b 2 AR-T4 lysozyme fusion protein used to obtain the high-resolution inactive state crystal structure 7, 9 .
We compared the effect of Nb80 with Gs on b 2 AR structure and agonist binding affinity. b 2 AR was labelled at the cytoplasmic end of transmembrane helix 6 (TM6) at Cys 265 with the fluorophore monobromobimane and reconstituted into high-density lipoprotein (HDL) particles. TM6 moves relative to TM3 and TM5 upon agonist activation ( Fig. 1a ), and we have shown previously that the environment around bimane covalently linked to Cys 265 changes with both agonist binding and G protein coupling, resulting in a decrease in fluorescence intensity and a red shift in l max 15 . As shown in Fig. 1b , the catecholamine agonist isoproterenol and Gs both stabilize an activelike conformation, but the effect of Gs is greater in the presence of isoproterenol, consistent with the cooperative interactions of agonist and Gs on b 2 AR structure. Nb80 alone has an effect on bimane fluorescence and l max of unliganded b 2 AR that is similar to that of Gs ( Fig. 1c ). This effect was not observed in b 2 AR bound to the inverse agonist ICI-118,551. The effect of Nb80 was increased in the presence of 10 mM isoproterenol. These results show that Nb80 does not recognize the inactive conformation of the b 2 AR, but binds efficiently to agonist-occupied b 2 AR and produces a change in bimane fluorescence that is indistinguishable from that observed in the presence of Gs and isoproterenol. Figure 1d and e shows the effect of Gs and Nb80 on agonist affinity for b 2 AR. b 2 AR was reconstituted into HDL particles and agonist competition binding experiments were performed in the absence or presence of Nb80 and Gs. In the absence of either protein, isoproterenol has an inhibition constant (K i ) of 107 nM. In the presence of Gs two affinity states are observed, because not all of the b 2 AR is coupled to Gs. In the Gs-coupled state the affinity of isoproterenol increases by 100fold (K i 5 1.07 nM) ( Fig. 1d and Supplementary Table 1 ). Similarly, in the presence of Nb80 the affinity of isoproterenol increases by 95-fold (K i 5 1.13 nM) ( Fig. 1e and Supplementary Table 1 ). In contrast, Nb80 had little effect on b 2 AR binding to the inverse agonist ICI-118,551 (Supplementary Fig. 1 and Supplementary Table 1 ). These binding data indicate that Nb80 stabilizes a conformation in wild-type b 2 AR that is very similar to that stabilized by Gs, such that the energetic coupling of agonist and Gs binding is faithfully mimicked by Nb80.
The high-resolution structure of the inactive state of the b 2 AR was obtained with a b 2 AR-T4L fusion protein. We showed previously that b 2 AR-T4L has a higher affinity for isoproterenol than wild-type b 2 AR 7 . Nevertheless, in the presence of Nb80 the affinity increased by 60-fold, resulting in an affinity (K i 5 0.56 nM) comparable to that of wild-type b 2 AR bound to Nb80 ( Fig. 1f and Supplementary Table 1 ). Although we cannot study G protein coupling in b 2 AR-T4L due to steric hindrance by T4L, the results show that T4L does not prevent binding of Nb80, and the nearly identical K i values for agonist binding to wild-type b 2 AR and b 2 AR-T4L in the presence of Nb80 indicate that Nb80 stabilizes a similar conformation in these two proteins. The most likely explanation for the ability of Nb80 to bind to b 2 AR-T4L whereas Gs does not is the difference in size of these two proteins. Nb80 is approximately 14 kDa whereas the Gs heterotrimer is approximately 90 kDa. illustrates the movement of the environmentally-sensitive bimane probe attached to Cys 265 6.27 in the cytoplasmic end of TM6 from a more buried, hydrophobic environment to a more polar, solvent-exposed position during receptor activation that results in a decrease in fluorescence in Fig. 1b-c and Supplementary Fig. 2c, d 
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High affinity b 2 AR agonist
To stabilize further the active state of the b 2 AR, we screened over 50 commercial and proprietary b 2 AR ligands. Of these, BI-167107 (Boehringer Ingelheim) had the most favourable efficacy, affinity and off-rate profile. BI-167107 is a full agonist that binds to the b 2 AR with a dissociation constant K d of 84 pM ( Supplementary Fig. 2a and b ). As shown in Supplementary Fig. 2c and d, BI-167107 induces a larger change in the fluorescence intensity and l max of bimane bound to Cys 265 than does the agonist isoproterenol. Moreover, the rate of dissociation of BI-167107 was extremely slow. Displacement of BI-167107 with an excess of the neutral antagonist alprenolol required 150 h to complete, compared with 5 s for isoproterenol.
Crystallization of b 2 AR-T4L-Nb80 complex
The b 2 AR was originally crystallized bound to the inverse agonist carazolol using two different approaches. The first crystals were obtained from b 2 AR bound to a Fab fragment that recognized an epitope composed of the amino and carboxyl terminal ends of the third intracellular loop connecting TMs 5 and 6 (ref. 8 ). In the second approach, the third intracellular loop was replaced by T4 lysozyme (b 2 AR-T4L) 7 . Efforts to crystallize b 2 AR-Fab complex and b 2 AR-T4L bound to BI-167107 and other agonists failed to produce crystals of sufficient quality for structure determination. We therefore attempted to crystallize BI-167107 bound to b 2 AR and b 2 AR-T4L
in complex with Nb80. Although crystals of both complexes were obtained in lipid bicelles and lipidic cubic phase (LCP), high-resolution diffraction was only obtained from crystals of b 2 AR-T4L-Nb80 grown in LCP. These crystals grew at pH 8.0 in 39-44% PEG400, 100 mM Tris, 4% DMSO and 1% 1,2,3-heptanetriol. A merged data set at 3.5 Å was obtained from 23 crystals (Supplementary Table 2 ). The structure was solved by molecular replacement using the structure of the carazolol-bound b 2 AR and a nanobody as search models. Supplementary Fig. 3a shows the packing of the b 2 AR-T4L-Nb80 complex in the crystal lattice. The receptor has interactions with lattice neighbours in several directions, and is relatively well ordered ( Supplementary Fig. 3a and b) , with readily interpretable electron density for most of the polypeptide. Nb80 binds to the cytoplasmic end of the b 2 AR, with the third complementaritydetermining region (CDR) loop projecting into the core of the receptor ( Fig. 2a, and Supplementary Fig. 4 ).
Agonist-stabilized changes in the b 2 AR 
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are relatively small changes in the extracellular surface (Fig. 2c) . The second intracellular loop (ICL2) between TM3 and TM4 adopts a two-turn alpha helix (Fig. 2d ), similar to that observed in the turkey b 1 AR structure 11 . The absence of this helix in the inactive b 2 AR structure may reflect crystal lattice contacts involving ICL2. Figure 2a and Supplementary Fig. 4a -c show details of interaction of Nb80 with the cytoplasmic side of the b 2 AR. An eight-amino-acid sequence of CDR3 penetrates into a hydrophobic pocket formed by amino acids from TM segments 3, 5, 6 and 7. A four-amino-acid sequence of CDR1 provides additional stabilizing interactions with cytoplasmic ends of TM segments 5 and 6. CDR3 occupies a position similar to the carboxyl terminal peptide of transducin in opsin 2 ( Supplementary Fig. 4c, d) . The majority of interactions between Nb80 and the b 2 AR are mediated by hydrophobic contacts.
When comparing the agonist-and inverse agonist-bound structures, the largest change is observed in TM6, with an 11.4-Å movement of the helix at Glu 268 6.30 (part of the ionic lock) (superscripts in this form indicate Ballesteros-Weinstein numbering for conserved GPCR residues 17 ) (Fig. 2d ). This large change is effected by a small clockwise rotation of TM6 in the turn preceding the conserved Pro 288 6.50 , enabled by the interrupted backbone hydrogen bonding at the proline and repacking of Phe 282 6.44 (see below), which swings the helix outward.
The changes in agonist-bound b 2 AR-T4L-Nb80 relative to the inactive carazolol-bound b 2 AR-T4L are remarkably similar to those observed between rhodopsin and opsin 2,3 (Fig. 2e ). The salt bridge in the ionic lock between highly conserved Arg 131 3.50 and Asp/ Glu 130 3.49 is broken. In opsin, Arg 135 3.50 interacts with Tyr 223 5.58 in TM5 and a backbone carbonyl of the transducin peptide. Arg 131 3.50 of b 2 AR likewise interacts with a backbone carbonyl of CDR3 of Nb80. However, Nb80 precludes an interaction between Arg 131 3.50 and Tyr 219 5.58 , even though the tyrosine occupies a similar position in opsin and agonist-bound b 2 AR-T4L-Nb80. As in opsin, Tyr 326 7.53 of the highly conserved NPxxY sequence moves into the space occupied by TM6 in the inactive state. In carazolol-bound b 2 AR-T4L we observed a network of hydrogen bonding interactions involving highly conserved amino acids in TMs 1, 2, 6 and 7 and several water molecules 7 . Although the resolution of the b 2 AR-T4L-Nb80 structure is inadequate to detect water molecules, it is clear that the structural changes we observe would substantially alter this network.
In contrast to the relatively large changes observed in the cytoplasmic domains of b 2 AR-T4L-Nb80, the changes in the agonist-binding pocket are fairly subtle. Figure 3 shows a comparison of the binding pockets of the inverse agonist-and agonist-bound structures. An omit map of the ligand-binding pocket is provided in Supplementary Fig. 5 . Many of the interactions between the agonist BI-167107 and the b 2 AR are similar to those observed with the inverse agonist carazolol. The alkylamine and the b-OH of both ligands form polar interactions with Asp 113 3.32 in TM3, and with Asn 312 7.39 
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agonist has a longer alkyl substituent on the amine, which ends with a phenyl ring that lies in a hydrophobic pocket formed by Trp 109 3.28 , Phe 193 5.32 and Ile 309 7.36 . The greatest difference between inactive and active structures in the ligand-binding site is an inward bulge of TM5 centred around Ser 207 5.46 , whose Ca position shifts by 2.1 Å (Fig. 4a ). In addition, there are smaller inward movements of TM6 and TM7. The basal activity shown by the b 2 AR indicates that the protein structure surrounding the binding pocket is relatively dynamic in the absence of ligand, such that it samples active and inactive conformations. The presence of Pro 211 5.50 in the following turn, which cannot form a hydrogen bond with the backbone at Ser 207 5.46 , is likely to lower the barrier to the transition between the conformations observed in the presence of carazolol and BI-167107. There are extensive interactions between the carbonyl oxygen, amine and hydroxyl groups on the heterocycle of BI-167107 and Ser 203 5.42 and 207 5.46 in TM5, as well as Asn 293 6.55 in TM6 and Tyr 308 7.35 in TM7. In contrast, there is only one polar interaction between the nitrogen in the heterocycle of carazolol and Ser 203 5.42 . Interactions of Ser 203 5.42 , Ser 204 5.43 and Ser 207 5.46 with catecholamine hydroxyls have been proposed, on the basis of mutagenesis studies showing that these serines are important for agonist binding and activation 18, 19 . Whereas Ser 204 5.43 does not interact directly with the ligand, it forms a hydrogen bond with Asn 293 6.55 on TM6, which is in turn linked to Tyr 308 7.35 of extracellular loop 3 (ECL3) (Fig. 3a ). This tyrosine packs against Phe 193 5.32 of ECL2, and both residues move to close off the ligandbinding site from the extracellular space.
Asn 293 6.55 contributes to enantiomeric selectivity for catecholamine agonists 20 . The b-OH of BI-167107 does not interact with Asn 293 6.55 , but forms hydrogen bonds with Asp 113 3.32 and Asn 312 7.39 , similar to what is observed for carazolol in the inactive structure. The chirality of the b-OH influences the spatial position of the aromatic ring system in b 2 AR ligands, so the effect of Asn 293 6.55 on b-OH enantiomeric selectivity may arise from its direct interaction with the aromatic ring system of the ligand, as well as its positioning of Ser 204 5.43 and Tyr 308 7.35 , which also interact with this portion of the ligand. However, BI-167107 is not a catecholamine, and it is possible that the b-OH of catecholamine agonists, such as adrenaline and noradrenaline, has a direct interaction with Asn 293 6.55 , because mutation of Asn 293 6.55 has a stronger influence on the preference for the chirality of the b-OH of catecholamine agonists, compared with non-catechol agonists and antagonists 20 . Trp 6.48 is highly conserved in Family A GPCRs, and it has been proposed that its rotameric state has a role in GPCR activation (rotamer toggle switch) 21 . We observe no change in the side chain rotamer of Trp 286 6.48 in TM6 (Fig. 4a) , which lies near the base of the ligandbinding pocket, although its position shifts slightly in concert with rearrangements of nearby residues Ile 121 3.40 and Phe 282 6.44 . Although there is spectroscopic evidence for changes in the environment of Trp 6.48 upon activation of rhodopsin 22 , a rotamer change is not observed in the crystal structures of rhodopsin and low-pH opsin. Moreover, recent mutagenesis experiments on the serotonin 5HT4 receptor demonstrate that Trp 6.48 is not required for activation of this receptor by serotonin 23 . These observations indicate that, although changes in hydrophobic packing alter the conformation of the receptor in this region, changes in the Trp 6.48 rotamer do not occur as part of the activation mechanism.
It is interesting to speculate how the small changes around the agonist-binding pocket are coupled to much larger structural changes in the cytoplasmic regions of TMs 5, 6 and 7 that facilitate binding of Nb80 and Gs. A potential conformational link is shown in Fig. 4 . Agonist interactions with Ser 203 5.42 and 207 5.46 stabilize a receptor conformation that includes a 2.1-Å inward movement of TM5 at position 207 5.46 and 1.4-Å inward movement of the conserved Pro 211 5.50 relative to the inactive, carazolol-bound structure. In the inactive state, the relative positions of TM5, TM3, TM6 and TM7 are stabilized by interactions between Pro 211 5.50 , Ile 121 3.40 , Phe 282 6.44 and Asn 318 7.45 . The position of Pro 211 5.50 observed in the agonist structure is incompatible with this network of interactions, and Ile 121 3.40 and Phe 282 6.44 are repositioned, with a rotation of TM6 around Phe 282 6.44 leading to an outward movement of the cytoplasmic end of TM6.
Although some of the structural changes observed in the cytoplasmic ends of transmembrane domains of the b 2 AR-T4L-Nb80 complex arise from specific interactions with Nb80, the fact that Nb80 and Gs induce or stabilize similar structural changes in the b 2 AR, as determined by fluorescence spectroscopy and by agonist binding affinity, suggests that Nb80 and Gs recognize similar agonist-stabilized conformations. The observation that the transmembrane domains of rhodopsin and the b 2 AR undergo similar structural changes upon activation provides further support that the agonist-bound b 2 AR-T4L-Nb80 represents an active conformation and is consistent with a conserved mechanism of G protein activation. However, the mechanism by which agonists induce or stabilize these conformational changes likely differs for different ligands and for different GPCRs. The conformational equilibria of rhodopsin and b 2 AR differ, as shown by the fact that rhodopsin appears to adopt a fully active conformation in the absence of a G protein 24 
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sampling can differ among different GPCRs, which likely gives rise to the variety of ligand efficacies displayed by these receptors. An agonist need only disrupt one key intramolecular interaction needed to stabilize the inactive state, as constitutive receptor activity can result from single mutations of amino acids from different regions of GPCRs 25 . Thus, disruption of these stabilizing interactions either by agonists or mutations lowers the energy barrier separating inactive and active states and increases the probability that a receptor can interact with a G protein.
METHODS SUMMARY
Crystallization. Preparation of b 2 AR-T4L and Nb80 are described in Methods. BI-167107-bound b 2 AR-T4L and Nb80 preincubated in 1:1.2 molar ratio were mixed in monoolein containing 10% cholesterol in 1:1.5 protein to lipid ratio (w/w). Initial crystallization leads were identified and optimized in 24-well glass sandwich plates using 50 nl protein:lipid drops overlaid with 0.8 ml precipitant solution in each well and sealed with a glass cover slip. Crystals for data collection were grown at 20 uC in hanging-drop format using 0.8 ml reservoir solution (36 to 44% PEG 400, 100 mM Tris pH 8.0, 4% DMSO, 1% 1,2,3-heptanetriol) diluted two-to fourfold in water. Crystals grew to full size, typically 40 3 5 3 5 mm 3 , within 7 to 10 days. Crystals were flash-frozen and stored in liquid nitrogen with reservoir solution as cryoprotectant. Diffraction data collection and processing, and structure solution and refinement are described in Methods.
